Puresta launches EVERQ, AI-powered skin-health platform

Puresta Lifestyle Private Limited announced the launch of EVERQ, an AI-powered skin-health platform designed to bring skin assessment, dermatologist consultations, personalised treatment and ongoing skincare together in one connected journey.

EVERQ is part of Puresta’s integrated skin-health ecosystem, which also includes SKINQ Rx and SKINQ. EVERQ serves as the consumer-facing platform connecting AI-led skin assessment with dermatologist-led care. SKINQ Rx provides targeted, dermatologist-led treatment solutions based on the consultation, while SKINQ extends the experience into clinically validated everyday and maintenance skincare.

The platform is being developed with a focus on Indian and melanin-rich skin, recognising that concerns such as pigmentation, acne, sensitivity and post-inflammatory marks can present differently across skin types. Puresta combines technology, dermatological expertise and data-led formulation as part of its approach to personalised skin health, with a focus on moving consumers away from generic product recommendations and towards solutions based on their individual skin needs.

With EVERQ, Puresta aims to move skincare from a primarily product-led experience towards a more personalised and outcome-led model. Rather than treating a consultation, prescription and skincare purchase as separate transactions, the platform is designed to retain context across the consumer’s care journey. As a consumer’s skin changes, the care journey can evolve with it.

The digital-first model also aims to make dermatologist-led skincare more accessible beyond India’s largest cities, reducing geography as a barrier to professional skin care.

Hitaysh Dhingraa, co-founder & CEO, Puresta, said: “India doesn’t have a skincare discovery problem. It has a diagnosis problem. Consumers have thousands of products and millions of recommendations, but very little clarity on what their skin actually needs. We built EVERQ around a simple philosophy — Diagnose First. Then Treat. AI helps us understand consumers and their skin at scale, dermatologists bring clinical judgement, and our ecosystem helps take that care from assessment through treatment and ongoing skincare. We don’t want to sell consumers more skincare. We want to help them use the right skincare.”

  • Related Posts

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs